Gloucestershire Health and Care- NHS Trust logo
with you, for you
Responses > Treatment of patients with Primary Immunodeficiency

Freedom of Information request Treatment of patients with Primary Immunodeficiency

Response published: 17 September 2025
Pharmacy

FOI Request

FOI request for the following data for Gloucestershire Health and Care NHS Foundation Trust: 1. The number of unique patients with a recorded diagnosis of Primary Immunodeficiency (PID) in Q2’25(April, May, and June 2025) a. Of these PID patients, what is the number of PID patients treated with Immunoglobulin in Q2’25(April, May, and June 2025) If possible, segment patients by brand used e.g 5 patients on Cuvitru b. How of these Ig treated PID patients are naïve (new starts) in Q2’25(April, May, and June 2025)? 2. The number of unique patients with a recorded diagnosis of Secondary Immunodeficiency (SID) in Q2’25(April, May, and June 2025) a. Of these SID patients, what is the number of SID patients treated with Immunoglobulin in Q2’25(April, May, and June 2025? If possible, segment patients by brand used? b. How of these Ig treated SID patients are naïve (new starts) in Q2’25(April, May, and June 2025)? 3. The number of unique patients with a recorded diagnosis of Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Q2’25(April, May, and June 2025) a. Of these SID patients, what is the number of CIDP patients treated with Immunoglobulin in Q2’25(April, May, and June 2025? If possible, segment patients by brand used? b. How of these Ig treated CIDP patients are naïve (new starts) in Q2’25(April, May, and June 2025)? 4. The number of immunoglobulin vials/volume in grams distributed to Gloucestershire Health and Care NHS Foundation Trust in each month for April, May, and June 2025, broken down by product (see below). I would also like to request the number of patients Gloucestershire Health and Care NHS Foundation Trust by brand if available: •Vigam •Flebogamma DIF •Gammaplex •Gamunex-C •Octagam •Gamten •Kiovig •Intratect •Privigen •Iqymune •Gammanorm •Subcuvia •Subgam •Hizentra •Hyqvia •Cuvitru •Panzyga •Xembify •Cutaquig • Vyvgart (Efgartigimod) Preferably I would like the data in .xlsx or .csv format. Alternatively a table will suffice Thanks for your support.

FOI Response

Freedom of Information Request – Ref: FOI 199-2025

 Thank you for your recent Freedom of Information request. Please find our response below.

You asked:

1. The number of unique patients with a recorded diagnosis of Primary Immunodeficiency (PID) in Q2’25(April, May, and June 2025)
a. Of these PID patients, what is the number of PID patients treated with Immunoglobulin in Q2’25(April, May, and June 2025) If possible, segment patients by brand used e.g 5 patients on Cuvitru
b. How of these Ig treated PID patients are naïve (new starts) in Q2’25(April, May, and June 2025)?

2. The number of unique patients with a recorded diagnosis of Secondary Immunodeficiency (SID) in Q2’25(April, May, and June 2025)
a. Of these SID patients, what is the number of SID patients treated with Immunoglobulin in Q2’25(April, May, and June 2025? If possible, segment patients by brand used?
b. How of these Ig treated SID patients are naïve (new starts) in Q2’25(April, May, and June 2025)?

3. The number of unique patients with a recorded diagnosis of Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in Q2’25(April, May, and June 2025)
a. Of these SID patients, what is the number of CIDP patients treated with Immunoglobulin in Q2’25(April, May, and June 2025? If possible, segment patients by brand used?
b. How of these Ig treated CIDP patients are naïve (new starts) in Q2’25(April, May, and June 2025)?

4. The number of immunoglobulin vials/volume in grams distributed to Gloucestershire Health and Care NHS Foundation Trust in each month for April, May, and June 2025, broken down by product (see below).

I would also like to request the number of patients Gloucestershire Health and Care NHS Foundation Trust by brand if available:

•Vigam
•Flebogamma DIF
•Gammaplex
•Gamunex-C
•Octagam
•Gamten
•Kiovig
•Intratect
•Privigen
•Iqymune
•Gammanorm
•Subcuvia
•Subgam
•Hizentra
•Hyqvia
•Cuvitru
•Panzyga
•Xembify
•Cutaquig
• Vyvgart (Efgartigimod)

Our response:

Gloucestershire Health and Care NHS Foundation Trust does not treat patients with PID, SID or CIDP.  Please re-direct your request to Gloucestershire Hospitals NHS Foundation Trust at ghn-tr.foi@nhs.net.

Next steps:

Should you have any queries in relation to our response, please do not hesitate to contact us. If you are unhappy with the response you have received in relation to your request and wish to ask us to review our response, you should write to:

Louise Moss
Head of Legal Services / Associate Director of Corporate Governance
c/o Gloucestershire Health and Care NHS Foundation Trust
Edward Jenner Court
1010 Pioneer Avenue
Gloucester Business Park
Brockworth, GL3 4AW
E-mail: louise.moss@ghc.nhs.uk

If you are not content with the outcome of any review, you may apply directly to the Information Commissioner’s Office (ICO) for further advice/guidance. Generally, the ICO will not consider your case unless you have exhausted your enquiries with the Trust which should include considering the use of the Trust’s formal complaints procedure. The ICO can be contacted at: The Information Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.